Biocom Bolsters Board with Policy and M&A Experts
Event summary
- Biocom added Aaron K. Cohen (Neurocrine Biosciences) and Bradley Wolff (Evercore) to its board on March 23, 2026.
- Cohen brings 25+ years in public policy and government affairs, with experience shaping healthcare legislation.
- Wolff has 25+ years in investment banking, specializing in healthcare M&A and capital markets transactions.
The big picture
Biocom's board additions reflect a strategic pivot toward deeper policy engagement and financial acumen as California's life science sector faces regulatory pressures and consolidation trends. The appointments come amid heightened industry scrutiny over healthcare legislation and cross-border dealmaking, areas where both Cohen and Wolff have proven track records.
What we're watching
- Policy Influence
- How Cohen's legislative experience will shape Biocom's advocacy amid evolving healthcare regulations.
- Deal Flow Dynamics
- Whether Wolff's M&A expertise accelerates strategic partnerships within Biocom's membership.
- Regional Expansion
- The pace at which Biocom integrates new board insights into its growing presence in Seattle and Tokyo.
Related topics